Biomarin Pharmaceutical Inc. logo

BMRN

Biomarin Pharmaceutical Inc.

$85.24

Earnings Summary

Revenue
$648.83Mn
Net Profits
$88.66Mn
Net Profit Margins
13.66%
PE Ratio
79.33

Highlights

Revenue:

Biomarin Pharmaceutical Inc.’s revenue jumped 9.43% since last year same period to $648.83Mn in the Q1 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 0.41% jump in its revenue since last 3-months.

Net Profits:

Biomarin Pharmaceutical Inc.’s net profit jumped 74.35% since last year same period to $88.66Mn in the Q1 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 335.15% jump in its net profits since last 3-months.

Net Profit Margins:

Biomarin Pharmaceutical Inc.’s net profit margin jumped 59.33% since last year same period to 13.66% in the Q1 2024. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 333.39% jump in its net profit margins since last 3-months.

PE Ratio:

Biomarin Pharmaceutical Inc.’s price-to-earnings ratio after this Q1 2024 earnings stands at 79.33.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Biomarin Pharmaceutical Inc. post its latest quarter earnings

EPS Estimate Current Quarter
0.35
EPS Estimate Current Year
0.35

Highlights

EPS Estimate Current Quarter:

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.35 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at 0.35.

Key Ratios

Key ratios of the Biomarin Pharmaceutical Inc. post its Q1 2024 earnings

Earning Per Share (EPS)
0.46
Return on Assets (ROA)
0.02
Return on Equity (ROE)
0.04

Highlights

Earning Per Share (EPS):

Biomarin Pharmaceutical Inc.’s earning per share (EPS) jumped 70.37% since last year same period to 0.46 in the Q1 2024. This indicates that the Biomarin Pharmaceutical Inc. has generated 70.37% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biomarin Pharmaceutical Inc.’s return on assets (ROA) stands at 0.02.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biomarin Pharmaceutical Inc.’s return on equity (ROE) stands at 0.04.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-04-26
0.35
0.46
31.43%